Tags

Type your tag names separated by a space and hit enter

Hyperlipidaemia in chronic kidney disease.
Ann Acad Med Singapore 2005; 34(1):31-5AA

Abstract

Cardiovascular disease is a major cause of mortality and morbidity in patients with chronic kidney disease (CKD). The prevalence of hyperlipidaemia or dyslipidaemias is much higher compared to the general population. Total or low-density lipoprotein (LDL) cholesterol is highest in patients with chronic renal impairment. The majority of patients with CKD do not develop renal failure; indeed, most of them die of cardiovascular causes before the development of renal failure. The K/DOQI (Kidney Disease Outcomes Quality Initiative) guidelines on dyslipidaemias in CKD suggest that all patients should therefore be evaluated for dyslipidaemias. They should have a complete fasting lipid profile with total, LDL and high-density lipoprotein cholesterol, and triglycerides measured to identify those at risk and those who require treatment. Generally, the treatment approach parallels that suggested by the National Cholesterol Education Program Adult Treatment Panel III guidelines, in which the main focus of treatment is the level of LDL cholesterol. Patients with CKD should be considered a "very high risk" category and aggressive therapeutic intervention initiated to reduce the risk of cardiovascular events.

Authors+Show Affiliations

Department of Renal Medicine, Singapore General Hospital, Singapore. grmccm@sgh.com.sg

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

15726217

Citation

Chan, C M.. "Hyperlipidaemia in Chronic Kidney Disease." Annals of the Academy of Medicine, Singapore, vol. 34, no. 1, 2005, pp. 31-5.
Chan CM. Hyperlipidaemia in chronic kidney disease. Ann Acad Med Singap. 2005;34(1):31-5.
Chan, C. M. (2005). Hyperlipidaemia in chronic kidney disease. Annals of the Academy of Medicine, Singapore, 34(1), pp. 31-5.
Chan CM. Hyperlipidaemia in Chronic Kidney Disease. Ann Acad Med Singap. 2005;34(1):31-5. PubMed PMID: 15726217.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Hyperlipidaemia in chronic kidney disease. A1 - Chan,C M, PY - 2005/2/24/pubmed PY - 2005/6/10/medline PY - 2005/2/24/entrez SP - 31 EP - 5 JF - Annals of the Academy of Medicine, Singapore JO - Ann. Acad. Med. Singap. VL - 34 IS - 1 N2 - Cardiovascular disease is a major cause of mortality and morbidity in patients with chronic kidney disease (CKD). The prevalence of hyperlipidaemia or dyslipidaemias is much higher compared to the general population. Total or low-density lipoprotein (LDL) cholesterol is highest in patients with chronic renal impairment. The majority of patients with CKD do not develop renal failure; indeed, most of them die of cardiovascular causes before the development of renal failure. The K/DOQI (Kidney Disease Outcomes Quality Initiative) guidelines on dyslipidaemias in CKD suggest that all patients should therefore be evaluated for dyslipidaemias. They should have a complete fasting lipid profile with total, LDL and high-density lipoprotein cholesterol, and triglycerides measured to identify those at risk and those who require treatment. Generally, the treatment approach parallels that suggested by the National Cholesterol Education Program Adult Treatment Panel III guidelines, in which the main focus of treatment is the level of LDL cholesterol. Patients with CKD should be considered a "very high risk" category and aggressive therapeutic intervention initiated to reduce the risk of cardiovascular events. SN - 0304-4602 UR - https://www.unboundmedicine.com/medline/citation/15726217/full_citation L2 - http://www.annals.edu.sg/pdf200502/ChanCM.pdf DB - PRIME DP - Unbound Medicine ER -